Prognostic Factors Associated With Failure of Total Elbow Replacement
Launched by UNIVERSITY OF MANCHESTER · Dec 31, 2024
Trial Information
Current as of September 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the reasons why some total elbow replacements (TER) may not work as well as expected. By looking at data from the National Joint Registry, which tracks elbow surgeries, researchers hope to find factors that could predict when a replacement might fail. The goal is to use this information to help improve surgery outcomes and reduce the need for additional surgeries, making the experience better for patients and their families.
To participate in this study, individuals need to be between 16 and 100 years old and must have had a primary total elbow replacement recorded in the National Joint Registry between April 1, 2012, and December 31, 2023. However, if someone did not agree to let their data be used for research or if there are issues tracing their information after surgery, they will not be included. While the study is not yet recruiting participants, it’s important for potential candidates to know that their involvement could contribute to improving future elbow surgeries for many people.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All patients aged 16 to 100 years old with a primary TER on the National Joint Registry (NJR) elbow dataset from the start of data collection on the 1st of April 2012 to the 31st of December 2023 will be included.
- Exclusion Criteria:
- • Patients are excluded if they did not consent for their data to be used for research purposes, if it is impossible to trace them after surgery, if their ID numbers are invalid, or if the surgery was not performed in England.
- • Unconfirmed procedures and procedures with inconsistent operative patterns (i.e. a sequence of operations where the primary operation is not the first operation in the sequence or where there are multiple primary operations recorded for the same joint) will be excluded from the analyses.
About University Of Manchester
The University of Manchester is a leading research institution known for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on multidisciplinary collaboration, the university leverages its extensive expertise in biomedical research and clinical practice to develop and evaluate new therapies and interventions. The institution is dedicated to improving patient outcomes and public health by conducting rigorous, ethically sound trials that adhere to the highest standards of scientific integrity. Through its state-of-the-art facilities and a robust network of healthcare partnerships, the University of Manchester actively contributes to the global body of medical knowledge and the translation of research findings into clinical applications.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Manchester, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported